Botulinum toxin is becoming a useful therapeutic toll for the treatment of many diseases in several disciplines. Following its application for regional movement disorders, such a s blepharospasm, strabismus, and spasmodic torticollis, this agent is now being used for the treatment of certain paln syndromes and in facial cosmetic applications. Despite the proliferation in use, issues involving the pharmacology of materials and bioeffects that are important to t h~s therapy are only partially understood. In this review, some recent published literature on newer applications and significant issues pertinent to this important technology are outlined. curr e p r i
hj-E d~\ a l -d Schanr;! a t t h e I -n i i e r s i t y of \Yisconsin: lio~ve~.er, thc n~~n l l ) e r of possil,lc :~pplicr~tions 11~1r.e incrzasecl considcral)l\. 0 1 cr the past 10 ! cL1rs. 'l'hc ~~n i c l u c pharmacologic properties of t h e nl;~tcl.i:~l h t~s added grcatl! tu tlie therapy for m;ln! ~~fflictions. Ilcspite nluch interest in tlie t c c l i n o l o g~. there are still man!. iss~lcs relating c c~ the mt~tcrials. n;ltllre o f tissue rcspoIises.
clinical applicarions th;~t are still ~~n r c s o l \ -c d .
~Ilchough b o t~~l i n u r n i n m u n o t ) p e I\ h~~s been t h e initill1 Llgcnr ~l s c d in t h e tre:ltnnent of spastic disorders. it is anticip;~tcd that inimunot! pc H \\-ill bccomc :I\-.tilal)lc in t h e near future. 'l'hc differences in clinical cfficxc! ;~n d safct! reprcscnt a sul)ject of imporr;~ncc. 'I'hc t i ) l l o~~ ing is ;I rc\ ie\\ of recent-l i r c r~~t~~r c ~u i d iinport~~nt topics relati! c to the I~otulinum therapeutic technolog!..
Blepharospasrn
13ot11lin~1rn toxin has I~cconle the tre:ltmcnt of choice for c s s c n t i~~l blcpharospas~n (t;ig. 1 ) ;~n d I~lcpliarospasm ;~sso-ciatecl \\.ith facial d>stoni:~, repI;~cing surgical pi-occci~~rcs :~n d mcdic;~cions as primar\ cllcr;~p!. Injections q i \ e n periodically to thc orhicul:~ris oc~rli muscle in se~.cr:~l Iocations PWT idc ;I ~n c t l l o d of r e d~r c i n g in\ ol~~nt;~r!-spasm rr.irhout destroying thc primfir!-:letion of I)linliing, I\ hiell is necessar!-to rnainr:tin the integrity of the ovr~lilr surf:,lcc.
Kcccntl!. ;~f t c r depletion. lor 70-1 1 of t h e proprietar!-R o t o~ has Occn replaceci with ne\\ s o u r c c m ;~r e~-i a l (13otox-(:I>(;/(:O lots), ~\ . h i c h is c~~r r c l l t l ! ~~s c c i in t h e I -nited States.
'l'he ne\\ source n l~~t c r i a l pro\ ides :In cffic;icio~~r agent: I~o \ \ e~. e r .
the c o~l l p i~l . ;~t i \ e cli1lic;11 tii.~ls II;I\C I -e~-c a l c d increased incidence of prosis compared I\ irh t h e origin:~l tri:lls. possibl!. indicating c11;lngt.s in t h e biolo~$c l,ctla\ -ior of chis nrT\-agent. I ' t o~i s can b e a\oidcci b! -using I o~~e r totill cioses (<40 1 1 ' ) 211~1 I>\-a\-oiding inJections into t h e lid cre;Isc or fold. I'tosis is generally re\ersiblc o\ er a period of I to 4 \\-cclis. 'l'llc cause of this complication relates to diffusion of the I>iol(,ic effect into the orl~ir with ~\.ealiening of t h e Ic\ ;Itor p:~lpebrae s~rperior m~~s c l c .
:\dditionally. ~l i p l o p i a a p p e a r s to l)c : I Inore Ilosing l e~c l s are much gre'ltcr than rccluircd for the treatment of blepl~arospasm-rclcttccl s\ ndromes, generally ranging from 100 11-to 300 I 1 (11 ith Hotox).
Recently. an effort to use more standardized endpoint\ in clinical studies of this condition has bccn t~nder~ra!. anci long-term efficacy is possible [1,2].
Contemporar!. issues relating to the use of I)otulinum toxin for this condition invol1-e i n d u c e d i n~m u n i t \ resulting from higher doses recluirecl for this affliction and possihle irnpuritics in t h e materi:lls being uscd (toxoici formation). Edward Schantz has pro\.icied a n excellent re\-ien. with respect to histor! of de\-clopmcnt and prociuction issues [3] .
Earlier coluparison :~n d e x p e r i e n c e has rc\caleci a discrepancy concerning the occurrence of this complication ('l'able 1 ) as it relates to dose. Recentl?-. the Hotox n i a n u f~i c t t~r e r , it has b e e n reported, has increased t h e purity (5pecific toxicity-activity, Allergen-(:I)(; lots) of tlie hasic mi~terials, rr.hich ma)-impact of inciiience of s e c o n d~~n resistance after repeated tlicrapcucic injections. D e s p i t e r e c o g n i t i o n o f t h e sccondar!. i m n i u n i t y problem. therapeutic efficac~-h a been lost for a signifi c a n t number o f p a t i e n t s \\-it11 c e r v i c a l d y s t o n i a l~e c a u s e t h e y h:lve dc\-eloped neutralizing antibodies to materials previously llsecl :IS therapeutic agents. For this reason. botulinum H toxin has b e e n d e \ e loped for therapeutic use. hlan)-a r t i c l c dealing \\it11 cer\.ical d\-stonia, pu1,lished in t h e ~~1 s t 2 years, deal rr it11 efficacy. dose finding, and safety st11dit.s involving the h o t~~l i n u m toxin immunotype R and immunot \ p e 1.' [-C,.S] . H o t u l i n l~i n t~p e F h;is h c c n used for patients n,ho are resistant t o type -1. H o n e v e r , resis- tancc to type E' can occur. and its occurrence appears to h e rclatecl to dose per injection cycle.
Assessing immunity status
C:on\.entionall!, thc luouse bioassay has been the gold standard for assessing a patient's immunity status. In the past, m a n y efforts have b e e n m a d e t o substitute t h e mouse bioassay \\.itti n o n -n e u t r a l i~i n g forms of :issa!-s (q, E1,ISA); horver-er, repeatedly t h e mouse I>io;~ssa!. has I x e n t h e best p r e d i c t~~r of future clinic:11 outcome. 'l'hc interpretation of discrep:~ncies I>etn.een ncutr:llizing and non-neutralizing LISS;I\S is thought to relate to differences in e p i t o p e sitc rcacti\ it! b c t n c c n r-arious forms of antibodies [6] .
' T h e e x p e n s e of t h e m o u s e 11eutraliz:ltion assay is considera1,le. \ I a n ) c l i n i c i a n s toda! a r e u s i n g t h e concept of remote point injections to a55ess the prese n c e of neutralizing antibodies in a resist:lnt patient.
T h e tcst inr olves t h e administering of ;In illjcction to a point t h a t is d i s t a n t from tlie d i s e a s e location, to asccrtain if a n-er~ltening effect could b e elicited. I f : I lveakening effect can b e elicited. ir r r o~~l d b e ~~n l i k c l ! that t h e patient response is l~e i n g effected I, ? A circu-I:lting neutralizing a n t i t~o d y . I f there is n o rveakening. it n,ould h e probable that t h e r e is a circu1:lting antit~o d y . 'l'his concept h:ls b e e n applied to t h e forellc:~d o n dy'tonia patient" w i t h brow excursion ;lnd foreh e a d \\.rinkle r e d u c t i o n recognized 11s t h e c a u s e o f r e m o t e p o i n t n . e a k n e \ s ( F i g . 3 ) ~111il 'I'able 2 ) .
I < l e c t r o~n y o g r ;~~~h y ( E h I G ) a s s e s s m e n t o n t h e l i m b s has also b e e n I I S C C~ to demonstrate t h e s:lme concept 171. ' The remote point effect \\ ith respect to forehead w e a k e n i n g has b e e n correlated n-ith t h e presence of neutralizing antibody ( s e e '['able 3 ) , a n d t h e s e findings have b e e n s~rhst:~nciated 161. 'l'he E\I(; anal!\i\ of extensor digitorurn brel-is correlated n-ith t h e antibody tcst for mouse bioassa! neutralization. 
Dosing problems with respect to therapeutic botulinum technology
T h e d i s c r c p a n c i c s in d o s e r e s p o n s e a m o n g various immunot!l>es. as \\ell as that a m o n g different preparat i o n s of t h e s a m e i n~m~l n o t~, p e , lia\.e c o n t i n u e d t o occupy tlie literature (11 er t h e past several \cars. '1%)-pc I: toxin has long b c c n known to h a w a shorter duration of action, hut recently it has been she\\-n to continue to ha\-e a shorter duration of action than i n i m~~n o t ) -p e A e\.en \\-it11 high doses 181. :\ltho~~,gli hotulinum type I3 has produced tissue effects that are similar to those achie\ ed \\ ith t!.pe A, studies have indicated a differe n c e \\it11 respect to potency and duration of actions IC),lO]. P o t e n c y d i f f e r e n c e s \\ c r c n o t e d in Iiindlinib r e g~o n a l denervation bioassa!-s in preparation from t h e s a m e i m r n~~n o t ) -p e ( F i g . 4 ) . hlcdical literature regarding t h e medicinal properties of 1,otulinuni t!pc H Itas a c c u n i~~l a t c d
[ l 1.121. 'l'he data she\\ efficac!. in using botulinum toxin t!pc H: IIo\\e\.er, t h e doses arc considerable (2500 to 10.000 11 .). .\ dose response rclationstlip has b e e n d e m o n s t r~l t e d , a n d a significant incid e n c e of dyspliagia \\-as sho\\.n t o b e a p r o b l e m a t higher doses.
'I'lic \ ar\,ing dose response relationships bet\\ c c n Hot(3.i and Dysport (Sp!.\\-ood/I'ortin: Idondon, E n l a n d ) has continued to I,e discussed in the literaturc o\ cr tlie past se\ era1 !-ears. I>ysport has hccn notccl to h e 3 to 4 times less cffccti\-c on a motlsc unit t):lsis t l i~~i \ \ a s Hotox. 
Newer complications identified with Botox
Keccntlv. dcrniatologic reactions ha\-c hccn reported in t h e \ icinity of the injection sites [I 51. Surprisingl!-, some clinicians using botulint~m toxin arc una\\ arc that therc a r e l i u m a~i blood p r o d u c t s \I itliin t h e \.ials ( h u m a n serum albumin). .\ltliougli uncommon, t h e albumin can occasionall\. cause a n allergic I-e,lction.
:\nother more serious systemic reaction from the Llse of I3otor .\ has I x e n reported recently. .\ p a t i e n t \\-it11 facial d!,skinesia (I,lepharospas~i~) de\.elopeci m! asthenia during a series of injections spanning 1.5 !-ears. I<\treme d\.sphagia. s e l e r e \\-eight loss, and p;lral!-sis of t h e face 
Newer indications
1ieccntl)-, the recognition that botulinum toxin call b e useful for the treatment of certain forms of pri~nary pain s > -n d r o m e s h a s h e e n r e c o g n i z e d 11 71. PIIany h a \ e confirmed t h e ~~s c f u l n c s s of t h e s e initill1 obser\-ations [lH,lO] . O t h e r studics she\\ l e s con\ incing results [20] . It I1215 heen \\-ell r c c o g n i~c d that pain is t h e most sensiti\ c and responsi\-e component of thc ccr\ ical d!-stonia s>-ndrome ['I]. :ldditionally, facial pain that is associated \\ ith aberrant ner\,e regeneration often responds to b o t t~l i n u m toxin injection. so it is not surprising that it is pofiibly efficacious in t h e trclltrnent of pain. .A direct effect o n the afferent sensor)-system has been postulated related to thc percei\wi henefit in human essential headache disorders 11 7,221.
iiddition:ll s t u d i e s arc clcarl) n e c d c d to perfect t h e application of b o t~~l i n u m toxin for tluman essential headaclics, myofascial pain s>-nclro~nes, or other pain applications. L o n g duration of action. s y s t e m i c s i d c cffect profile, a n d the absence of patient self-medicatio~i 1ii;1y psovide distinct adlantagcs for this therapy in the s p c u r~~~~l of p i n rnan:lgcmcnt.
'I'he e x p a n s i o n i n h e a d a c h e apl,lication n o \ \ h~~s included migraine. I'aticnts treated f o~. cosmetic \vrinlilc ~. c d u c t i o n h a \ -e n o t e d i m p r o \ c n I c n t in c s s e~l t i a l headaches, i n c l u d i n g migraine. Similar ol,scr\.ations ha\-c been made in patients rccci\.ing t h e injection for t h e t r e a t m e n t of b l e p h a r o s p a s m . LA regional c f f e c t in\-olving pain rcd~lction is often noted ~lround the injcction sites that is consistent \\ith botulinum toxin's diffusion potential. Over the past sc\cral months, ~lpplication in migraine as \\ell as ot1ic1-forms of e s s c n t i~~l Iicad:~che d i s o r d e r s \ \ i l l b e t h e s u b j e c t of p l a c e b o c o n t r o l l e d studies, \\ liicli are I~e i n g conducted at this writing. 'l'his application also fits tlic h>pothesis that 1,otulinum toxin has a direct effect on the sensory side of t h e peripheral ner\-ous s y s t e m . 'l'he n a t u r e of this e f f e c t \\-ill most
